RxDoctor Payments Data

Patrick Duncan, MD

Pulmonary Disease · Saint Louis, MONPI 1326577172

Payments from drug & device makers

$9,441in general payments, 2019–2025

Across 193 payments — averaging $48.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AstraZeneca$902
  • GSK$814
  • Boehringer Ingelheim$267
  • Insmed, Inc.$257
  • Regeneron Healthcare Solutions, Inc.$209
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$1,20313%
  • Food & beverage$4,23845%
  • Education$4,00042%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,441 in reported general payments places this provider in the 70th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$170,690
Medicare patients
503
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter271$236,954
Breztri AerosphereBudesonide/Glycopyr/Formoterol133$124,470
Aralast NpAlpha-1-Proteinase Inhibitor12$119,960
Breo ElliptaFluticasone/Vilanterol85$48,446
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$36,069
SymbicortBudesonide/Formoterol Fumarate99$35,496
EliquisApixaban25$31,750
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate118$28,408
Spiriva RespimatTiotropium Bromide20$19,490
DuleraMometasone/Formoterol24$12,393
ArexvyRsvpref3 Antigen/As01e/Pf27$6,714
Albuterol Sulfate HfaAlbuterol Sulfate238$6,501
Qvar RedihalerBeclomethasone Dipropionate22$5,831
Advair HfaFluticasone Propion/Salmeterol11$5,544
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy$814$328,182443 claims
AstraZenecaBreztri Aerosphere, Symbicort$902$159,966232 claims
Boehringer IngelheimSpiriva Respimat$267$19,49020 claims
MerckDulera$143$12,39324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →